---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-088606"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:37:11.843821+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cellectar reports Q2 2024 cash of $25.9M; pivotal WM trial shows 80% ORR, exceeding primary endpoint

## Summary
- Cash and equivalents $25.9M as of June 30, 2024, up from $9.6M at Dec 31, 2023. Net cash used in ops Q2 2024 was $14.1M.
- R&D expense $8.2M (Q2 2024) vs $6.3M (Q2 2023); G&A $6.4M vs $2.0M.
- CLOVER WaM study: 80% ORR, 56.4% MRR exceeded primary endpoint of 20% MRR; median prior lines of therapy was 4.
- NDA filing for iopofosine I 131 in WM planned for Q4 2024; accelerated 6-month review; potential 2025 launch.
- Raised $19.4M in July 2024; cash runway into Q2 2025.

## SEC filing metadata
- accession: 0001104659-24-088606
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924088606/0001104659-24-088606-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924088606/tm2421529d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-088606
- JSON: https://secwatch.observer/filing/0001104659-24-088606.json
- Plain text: https://secwatch.observer/filing/0001104659-24-088606.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.